D. Vaughn

S. Singhal, D. Vaughn, Armin Farazdaghi, 2019, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen.

R. Mick, A. Wein, D. Vaughn, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of address-based sampling and random-digit dialing methods for recruiting young men as controls in a case-control study of testicular cancer susceptibility.

K. Nathanson, N. Mitra, D. Vaughn, 2013, American journal of epidemiology.

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.

E. Plimack, T. Guzzo, A. Balar, 2019, The oncologist.

Cancers of the large bowel and hepatobiliary tract.

D. Vaughn, V. Avilés, 1999, Cancer chemotherapy and biological response modifiers.

A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer.

E. Plimack, G. Hudes, D. Vaughn, 2012, Seminars in oncology.

Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors

David C. Smith, E. Basch, D. Hayes, 2010 .

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

G. Sonpavde, M. Galsky, M. Milowsky, 2013, European urology.

Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide

Eun Jeong Min, Qi Long, K. Wellen, 2020, Prostate Cancer and Prostatic Diseases.

Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy

R. Frisina, R. Huddart, D. Feldman, 2021, Cancer medicine.

Recent developments in chemotherapy for bladder cancer.

D. Vaughn, S. Malkowicz, 2001, Oncology.

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

David C. Smith, M. Kohli, D. Petrylak, 2014, Cancer.

Reply to S. Buti and S. Culine.

E. Plimack, S. Litwin, G. Hudes, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of objective and patient-reported hot flash measures in men with prostate cancer.

J. Coyne, S. Marcus, S. Palmer, 2009, The journal of supportive oncology.

Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer

R. Frisina, M. Dolan, D. Feldman, 2022, Cancer medicine.

A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)

J. Berlin, S. Adak, D. Vaughn, 2000, Oncology.

Guideline discordant care in patients with metastatic germ cell tumors.

L. Shulman, D. Vaughn, L. Jacobs, 2022, Urologic oncology.

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

N. Hanna, D. Feldman, L. Einhorn, 2022, Investigational New Drugs.

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

J. Manola, G. Wilding, W. See, 2002, Cancer.

Inflammatory Myofibroblastic Tumors of the Urinary Tract: A Clinicopathologic Study of 46 Cases, Including a Malignant Example Inflammatory Fibrosarcoma and a Subset Associated With High-grade Urothelial Carcinoma

E. Montgomery, J. Epstein, C. Griffin, 2006, The American journal of surgical pathology.

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

T. Guzzo, S. Malkowicz, V. Narayan, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma

David C. Smith, S. Srinivas, C. Sternberg, 2009, Cancer.

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

J. Gutheil, D. Vaughn, M. Hussain, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

D. Haller, P. O'dwyer, D. Vaughn, 2001, Cancer.

A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial.

D. Haller, D. Vaughn, C. Holroyde, 2000, American journal of clinical oncology.

Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC).

G. Adluru, K. Flaherty, A. Troxel, 2009, Journal of Clinical Oncology.

Chemotherapy for patients with poor prognosis germ cell tumors

M. Riese, D. Vaughn, Matthew J. Riese, 2009, World Journal of Urology.

Poor-prognosis germ cell tumors: we have not yet crossed the finish line.

D. Vaughn, E. Stadtmauer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Third-line chemotherapy and novel agents for metastatic germ cell tumors.

D. Vaughn, Christine M. Veenstra, 2011, Hematology/oncology clinics of North America.

Reply to J. Beyer, T. Tandstad et al, S. Gillessen et al, J. Oldenburg et al, and L.C. Pagliaro et al.

D. Vaughn, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primum non nocere: active surveillance for clinical stage I testicular cancer.

D. Vaughn, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Medical Care of Testicular Cancer Survivors

D. Vaughn, A. Meadows, G. Gignac, 2003, Annals of Internal Medicine.

Hypogonadism and infertility in testicular cancer survivors.

D. Vaughn, L. Jacobs, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy.

M. Ratajczak, A. Gewirtz, D. Vaughn, 2001, Blood.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

G. Pond, P. Albers, T. Choueiri, 2013, European urology.

Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.

M. Rosen, W. Hwang, P. O'dwyer, 2016, Clinical genitourinary cancer.

Thromboembolic events with estramustine phosphate‐based chemotherapy in patients with hormone‐refractory prostate carcinoma

J. Berlin, D. Vaughn, G. Lubiniecki, 2004, Cancer.

GERM CELL TUMOURS

Dong Seok Kim, Teo Wan Yee, R. Gibbs, 2014, The Ulster Medical Journal.

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

G. Sonpavde, M. Ernstoff, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

combination chemotherapy Investigating the platelet-sparing mechanism of paclitaxel/carboplatin

M. Ratajczak, D. Vaughn, M. Majka, 2011 .

A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer.

L. Shaw, D. Haller, D. Vaughn, 1998, American journal of clinical oncology.

PD0332991 (Palbociclib) for treatment of pediatric intracranial growing teratoma syndrome

D. Vaughn, A. Bendel, J. Petronio, 2015, Pediatric blood & cancer.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone‐Refractory Prostate Carcinoma: ECOG‐ACRIN Cancer Research Group (E1898) Trial

J. Manola, D. Cella, J. Moul, 2017, Clinical genitourinary cancer.

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

Ronac Mamtani, W. Bilker, A. Ferrara, 2015, JAMA.

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen‐independent prostate carcinoma

F. Kabbinavar, D. Vaughn, W. G. Harker, 2004, Cancer.

Phase II Trial of Toremifene in Androgen‐Independent Prostate Cancer: A Penn Cancer Clinical Trials Group Trial

S. Stein, D. Haller, D. Vaughn, 2001, American journal of clinical oncology.

A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma

R. Figlin, E. Small, D. Petrylak, 2000, Investigational New Drugs.

Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas.

E. Rosato, M. Berry, D. Haller, 2000, International journal of radiation oncology, biology, physics.

S. Culine, M. Climent, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Investigation : Genitourinary Cancer A Novel Risk Stratification to Predict Local-Regional Failures in Urothelial Carcinoma of the Bladder After Radical Cystectomy

T. Guzzo, W. Hwang, S. Malkowicz, 2022 .

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

L. Collette, S. Culine, R. Huddart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors.

N. Hanna, D. Feldman, L. Einhorn, 2020 .

Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.

T. Guzzo, C. Deville, W. Hwang, 2011, International journal of radiation oncology, biology, physics.

Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy.

T. Guzzo, C. Deville, W. Hwang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of early hospital discharge in adult patients with fever and neutropenia.

K. Fox, D. Vaughn, N. Meropol, 1994, European journal of cancer.

Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial

C. Sternberg, D. Petrylak, O. Sartor, 2007 .

Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer.

E. Plimack, S. Litwin, G. Hudes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer.

E. Plimack, S. Litwin, S. Cohen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic Prostate Cancer

D. Vaughn, B. Malkowicz, B. Levin, 2003 .

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

E. Small, J. Pérez-Ruixo, J. Rosenberg, 2005, Cancer.

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Weijing Sun, Daniel G Haller, Mark Rosen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.

M. Somerfield, C. Shapiro, D. Vaughn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.

David C. Smith, E. Basch, D. Hayes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility.

H. Hakonarson, Mingyao Li, M. Reilly, 2011, Human molecular genetics.

Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer

Nandita Mitra, Muredach P Reilly, Andrew K Godwin, 2009, Nature Genetics.

The Y deletion gr/gr and susceptibility to testicular germ cell tumor.

M. Pike, M. Stratton, D. Forman, 2005, American journal of human genetics.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

S. Culine, M. Climent, T. Choueiri, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors.

N. Rahman, S. Chanock, M. Greene, 2014, Human molecular genetics.

Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.

P. Lal, S. Sadigh, D. Vaughn, 2019, American journal of clinical pathology.

Treatment of growing teratoma syndrome.

K. Flaherty, K. Wilner, P. Lal, 2009, The New England journal of medicine.

Effects of Bowman–Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia * †

A. Wein, K. Propert, W. Mckenna, 2001, The Prostate.

Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder

D. Vaughn, E. Stadtmauer, D. Tsai, 1998, Medical oncology.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

R. Berger, M. Galsky, D. Bajorin, 2018, Cancer discovery.

Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.

M. Feldman, A. DeMichele, P. O'dwyer, 2016, JAMA oncology.

Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors

Nathanael D. Moore, D. Rader, E. V. Van Allen, 2019, JAMA oncology.

Identification of 22 susceptibility loci associated with testicular germ cell tumors

Christopher D. Brown, L. Kiemeney, K. Stefánsson, 2021, Nature Communications.

Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial

J. Witjes, C. Sternberg, D. Petrylak, 2008 .

Somatic genetics of testicular cancer in relationship to prognosis

K. Nathanson, D. Vaughn, 2004 .

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.

P. Catalano, G. Wilding, L. Einhorn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

S. Culine, T. Choueiri, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

L. Collette, R. Huddart, C. Bokemeyer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

E. Gamazon, S. Fosså, M. Dolan, 2017, Clinical Cancer Research.

Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer

V. Narayan, D. Vaughn, 2015, Expert opinion on drug metabolism & toxicology.

Complications associated with chemotherapy in testicular cancer management

D. Vaughn, C. Fung, 2011, Nature Reviews Urology.

Phase I Study of Weekly Liposome-Encapsulated Doxorubicin in Patients With Advanced, Androgen-Independent Prostate Cancer

K. Flaherty, S. Malkowicz, D. Vaughn, 2004, American journal of clinical oncology.

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.

C. Thorn, D. Haller, P. O'dwyer, 2004, European journal of cancer.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

D. Heitjan, A. Nixon, S. Eliasof, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.

S. Steinberg, P. Johnston, C. Takimoto, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Kevin Haynes, Karen Glanz, Ronac Mamtani, 2012, Journal of the National Cancer Institute.

HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma.

W. Rathmell, D. Vaughn, M. Simon, 2004, Anticancer research.

Percutaneous ethanol ablation of an adrenal tumor.

A. Alavi, H. Nisenbaum, D. D. Maki, 2000, AJR. American journal of roentgenology.

Inflammatory bowel disease is not associated with an increased risk of lymphoma.

C. Brensinger, B. Strom, D. Vaughn, 2001, Gastroenterology.

Are patients with inflammatory bowel disease (IBD) at increased risk for lymphoma

W. Bilker, C. Brensinger, B. Strom, 2000 .

Cardiovascular toxicities of therapy for genitourinary malignancies.

V. Narayan, B. Ky, D. Vaughn, 2020, Urologic oncology.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Nancy J Cox, Robert D Frisina, M Eileen Dolan, 2014, Journal of the National Cancer Institute.

Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

M. Dolan, D. Feldman, L. Einhorn, 2020, Clinical Cancer Research.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

S. Fosså, H. Sesso, S. Lipshultz, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiovascular risk in long‐term survivors of testicular cancer

S. Palmer, E. Mohler, D. Vaughn, 2008, Cancer.

Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors

M. Rosen, W. Hwang, P. Lal, 2015, Cancer.

Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).

David C. Smith, A. Belldegrun, M. Kohli, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies in germ cell tumors.

D. Vaughn, C. Squillante, 2015, Urologic oncology.

The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis

S. Sonnad, T. Guzzo, D. Vaughn, 2008, BJU international.

Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.

D. Vaughn, 2008, Cancer treatment reviews.

Recent Advances in Bladder Cancer Chemotherapy

D. Vaughn, S. Malkowicz, 2001, Cancer investigation.

Paclitaxel and carboplatin in bladder cancer: recent developments.

D. Vaughn, 2000, European journal of cancer.

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

G. Sonpavde, M. Ernstoff, M. Carducci, 2014, Cancer.

Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?

T. Guzzo, D. Vaughn, S. Hilton, 2020, Urologic oncology.

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy

Frederick G. Strathmann, S. Fosså, M. Dolan, 2019, Clinical Cancer Research.

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206

L. Einhorn, N. Hanna, C. Albany, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose cytarabine neurotoxicity: MR findings during the acute phase.

D. Hackney, J. Jarvik, D. Vaughn, 1993, AJNR. American journal of neuroradiology.

Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study

S. Fosså, R. Huddart, K. Kroenke, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.

P. O'dwyer, D. Vaughn, L. Schuchter, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.

D. Haller, P. O'dwyer, D. Vaughn, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer

Ravi B. Parikh, R. Hubbard, J. Cashy, 2021, JAMA network open.

Chronic lymphocytic leukemia: an unusual cause of upper gastrointestinal hemorrhage.

D. Faigel, E. Furth, D. Metz, 1995, The American journal of gastroenterology.

Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

K. Nathanson, W. Hwang, V. Narayan, 2016, Clinical genitourinary cancer.

Neoadjuvant chemotherapy in patients with invasive bladder cancer.

S. Malkowicz, D. Vaughn, 2005, The Urologic clinics of North America.

Neoadjuvant Chemotherapy in Bladder Cancer

S. Malkowicz, D. Vaughn, G. Lubiniecki, 2005 .

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

C. Obasaju, F. Kabbinavar, D. Vaughn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors

R. Frisina, S. Fosså, R. Huddart, 2020, JNCI cancer spectrum.

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

S. Fosså, M. Dolan, R. Huddart, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

S. Fosså, R. Huddart, H. Sesso, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sporadic Zollinger-Ellison syndrome with ectopic production of corticotropin: surgical management.

E. Furth, D. Metz, D. Vaughn, 1999, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Chemotherapy for clinical stage I nonseminomatous germ cell tumours

D. Vaughn, 2009, BJU international.

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer

W. Bilker, A. Ferrara, B. Strom, 2014, Pharmacoepidemiology and drug safety.

Bilateral Lung Transplantation for Bleomycin-Associated Lung Injury.

V. Narayan, D. Vaughn, C. Bermudez, 2017, The oncologist.

Epigenetic age acceleration in U.S. testicular cancer survivors (TCS).

K. Nathanson, D. Vaughn, L. Travis, 2022, Journal of Clinical Oncology.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin‐based Chemotherapy: Application of the Framingham Risk Score

R. Frisina, S. Fosså, M. Dolan, 2018, Clinical genitourinary cancer.

Cardiovascular risk in testicular cancer survivors treated with chemotherapy: incidence, significance, and practice implications.

D. Vaughn, L. Jacobs, B. Zoltick, 2005, Oncology nursing forum.

Leuprolide acetate (once-yearly implant): profile report

J. Moul, D. Vaughn, 2012 .

Leuprolide Acetate

D. Vaughn, 2003 .

Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.

S. Palmer, A. Wein, S. Malkowicz, 2008, Urology.

A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

G. Pond, P. Albers, T. Choueiri, 2014, BJU international.

Vinflunine in the treatment of advanced bladder cancer

D. Vaughn, R. Mamtani, 2011, Expert review of anticancer therapy.

Moving forward in advanced bladder cancer.

D. Vaughn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial.

D. Haller, D. Mintzer, D. Vaughn, 1997, American journal of clinical oncology.

A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer.

D. Haller, D. Vaughn, N. Meropol, 1996, American Journal of Clinical Oncology.

Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation.

T. Guzzo, C. Deville, N. Vapiwala, 2014, International journal of radiation oncology, biology, physics.

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

T. Powles, E. Plimack, A. Balar, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of 5-Fluorouracil and Leucovorin in Combination With Interferon-alpha and Interleukin-2 for Advanced Renal Cell Cancer

W. Rathmell, S. Malkowicz, D. Vaughn, 2004, American journal of clinical oncology.

Hormonal Therapy for Advanced Prostate Cancer

D. Vaughn, D J Vaughn, 2000, Annals of Internal Medicine.

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

E. White, R. DiPaola, G. Wilding, 2010, Journal of Translational Medicine.

Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2018 .

Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium.

A. Wein, D. Vaughn, S. Malkowicz, 1997, Seminars in Oncology.

Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.

Ravi B. Parikh, R. Hubbard, M. Galsky, 2019, European urology.

4534 POSTER Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)

David C. Smith, S. Srinivas, D. Petrylak, 2007 .

Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)

David C. Smith, S. Srinivas, D. Petrylak, 2007 .

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis.

Ravi B. Parikh, M. Galsky, S. Baxi, 2019, Future oncology.

A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.

T. Guzzo, W. Hwang, S. Malkowicz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association study between polymorphisms in DNA methylation-related genes and testicular germ cell tumor risk.

L. Kiemeney, D. Bishop, S. Chanock, 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Transrectal radiofrequency ablation for pelvic recurrence of bladder cancer: case report and review of complications.

M. Soulen, S. Rubesin, S. Horii, 2005, Journal of vascular and interventional radiology : JVIR.

What radiologists should know about microRNA (miRNA) serum biomarkers for germ cell tumors

D. Vaughn, M. Morgan, Joanie Garratt, 2020, Abdominal Radiology.

Health behaviors among testicular cancer survivors.

S. Palmer, D. Vaughn, L. Jacobs, 2012, The Journal of community and supportive oncology.

Cavernous sinus syndrome in Hodgkin's disease.

S. Kasner, S. Galetta, D. Vaughn, 1996, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Adult type granulosa cell tumor in adult testis: report of a case and review of the literature

D. Vaughn, Z. Bing, Zhao Song, 2011, Rare tumors.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

Chad A. LaGrange, David C. Smith, W. Lowrance, 2019 .

Assessment of coronary heart disease risk in testicular cancer survivors.

E. Mohler, D. Vaughn, C. Fung, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interest in services among prostate cancer patients receiving androgen deprivation therapy

J. Coyne, S. Palmer, S. Malkowicz, 2004, Psycho-oncology.

Association Among Hypoxemia, Patent Foramen Ovale, and Mediastinal Germ Cell Tumor: A Case Report

B. Ky, D. Vaughn, M. Offin, 2015, Annals of Internal Medicine.

Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).

N. Hanna, L. Einhorn, C. Albany, 2017 .

Chemotherapy for good-risk germ cell tumors: current concepts and controversies.

D. Vaughn, 2007, The Urologic clinics of North America.

Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments

R. Frisina, S. Fosså, R. Huddart, 2022, Ear and hearing.

Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF)

K. Nathanson, N. Mitra, D. Vaughn, 2012, Front. Endocrin..

Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy

R. Frisina, S. Fosså, H. Sesso, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increases in core body temperature precede hot flashes in a prostate cancer patient

J. Coyne, P. Gehrman, J. Mao, 2009, Psycho-oncology.

Impact of adjuvant chemotherapy on patients with lymph node metastasis at the time of radical cystectomy.

T. Guzzo, S. Malkowicz, D. Vaughn, 2010, The Canadian journal of urology.

Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer.

Christine E. Edmonds, D. Mankoff, M. Feldman, 2015 .

Germline Exome Sequencing for Men with Testicular Germ Cell Tumor Reveals Coding Defects in Chromosomal Segregation and Protein-targeting Genes.

H. Hakonarson, D. Rader, M. Greene, 2023, European urology.

Principles and reality of proton therapy treatment allocation.

D. Asch, S. Hahn, D. Vaughn, 2014, International journal of radiation oncology, biology, physics.

Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research.

T. Ten Have, T. Guzzo, D. Polsky, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy.

T. Guzzo, C. Deville, W. Hwang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CHAPTER 16 – Renal, Testicular, and Penile Cancer

D. Vaughn, R. Sánchez-Ortiz, 2007 .

3538 Eus downstaging of esophageal cancer by chemotherapy ± radiotherapy does not predict improved survival.

G. Ginsberg, P. Pfau, D. Haller, 2000 .

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic hormone refractory prostate cancer: results of ECOG 3899

J. Manola, R. DiPaola, G. Wilding, 2004 .

Effects of Bowman–Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia * †

K. Propert, D. Vaughn, S. Malkowicz, 2001, The Prostate.

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, T. Choueiri, D. Bajorin, 2022, Journal of Clinical Oncology.

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

S. Culine, M. Climent, T. Choueiri, 2019, Annals of Oncology.

Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.

T. Powles, M. Climent, E. Plimack, 2022, Journal of Clinical Oncology.

LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

S. Culine, M. Climent, T. Choueiri, 2017 .

Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2017 .

Evaluation of a web‐based weight loss intervention in overweight cancer survivors aged 50 years and younger

Shannon M. Lynch, S. Domchek, K. Schmitz, 2017, Obesity science & practice.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

J. Hajdenberg, R. Motzer, D. Feldman, 2013, Investigational New Drugs.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1.

J. Christensen, A. DeMichele, P. O'dwyer, 2011, Journal of Clinical Oncology.

Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, M. Climent, T. Choueiri, 2018 .

Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors

M. Rosen, W. Hwang, P. Lal, 2015, Cancer.

Three Cases of Advanced Seminoma and Down's Syndrome: A Possible Association

D. Vaughn, R. Whittington, K. V. Arsdalen, 2003, American journal of clinical oncology.

A SHORT TEXTBOOK OF MEDICINE

Dong Seok Kim, Teo Wan Yee, R. Gibbs, 1973, The Ulster Medical Journal.

Testicular Seminoma 16 Years After Treatment for CNS Germinoma

H. Shu, A. Maity, A. Judkins, 2004, Journal of Neuro-Oncology.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

S. Fosså, R. Huddart, H. Sesso, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Cisplatin and 5-Fluorouracil (PF) and Mitomycin C, Vincristine, Cisplatin and 5-Fluorouracil (MVPF) in Patients with Metastatic Large Bowel Cancer: An Eastern Cooperative Oncology Group Study (EST 1285)

N. Petrelli, D. Haller, D. Vaughn, 2004, Oncology.

Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).

S. Fosså, H. Sesso, D. Feldman, 2017 .

Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.

S. Fosså, R. Huddart, H. Sesso, 2017 .

Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene.

R. Frisina, E. Gamazon, M. Dolan, 2016 .

Lower abdominal and pelvic radiation and testicular germ cell tumor risk

K. Nathanson, N. Mitra, D. Vaughn, 2020, PloS one.

Editorial comment on "Late relapse of testicular germ cell tumors".

D. Vaughn, 2005, Urologic oncology.

Malignant Melanoma Arising in a Primary Mediastinal Teratoma: Case Report of a Rare Phenomenon and Review of the Literature

D. Elder, S. Singhal, P. Lal, 2022, AJSP: Reviews and Reports.